|
JPS5145405A
(ja)
*
|
1974-10-16 |
1976-04-17 |
Unyusho Kowan Gijutsu Kenkyush |
Jibankairyokoho
|
|
JPS53115509A
(en)
*
|
1977-12-19 |
1978-10-09 |
Kitagawa Iron Works Co |
Method of changing weak ground into stable ground
|
|
JPS53115510A
(en)
*
|
1977-12-19 |
1978-10-09 |
Kitagawa Iron Works Co |
Support structure made by hardening weak soil
|
|
DE2917535C2
(de)
*
|
1979-04-30 |
1986-10-30 |
Hoechst Ag, 6230 Frankfurt |
Gegen Denaturierung beständige Insulinlösungen
|
|
EP0083619A1
(fr)
*
|
1981-07-17 |
1983-07-20 |
Nordisk Insulinlaboratorium |
Preparation therapeutique d'insuline aqueuse stable et son procede de preparation
|
|
CH657779A5
(de)
*
|
1982-10-05 |
1986-09-30 |
Sandoz Ag |
Galenische zusammensetzungen enthaltend calcitonin.
|
|
JPH0625068B2
(ja)
*
|
1982-12-10 |
1994-04-06 |
シンテツクス（ユ−・エス・エ−・）インコ−ポレイテイド |
鼻腔内投与用組成物及びその製造方法
|
|
AU572815B2
(en)
*
|
1982-12-29 |
1988-05-19 |
Armour Pharmaceutical Company |
Pharmaceutical calcitonin compositions for intranasal application
|
|
JPS59163313A
(ja)
*
|
1983-03-09 |
1984-09-14 |
Teijin Ltd |
経鼻投与用ペプチドホルモン類組成物
|
|
US4746508A
(en)
*
|
1983-06-06 |
1988-05-24 |
Beth Israel Hospital Assn. |
Drug administration
|
|
US4548922A
(en)
*
|
1983-06-06 |
1985-10-22 |
Beth Israel Hospital |
Drug administration
|
|
DE3443877A1
(de)
*
|
1984-06-09 |
1985-12-12 |
Hoechst Ag |
Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
|
|
US4658830A
(en)
*
|
1984-08-08 |
1987-04-21 |
Survival Technology, Inc. |
Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
|
|
IL78425A
(en)
*
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
|
AU584184B2
(en)
*
|
1985-04-15 |
1989-05-18 |
Eli Lilly And Company |
An improved method for administering insulin
|
|
GB2177914B
(en)
*
|
1985-06-04 |
1989-10-25 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
|
|
US4692441A
(en)
*
|
1985-08-16 |
1987-09-08 |
Merck & Co., Inc. |
Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
|
|
US4731360A
(en)
*
|
1985-08-16 |
1988-03-15 |
Merck & Co., Inc. |
Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
|
|
DK179286D0
(da)
*
|
1986-04-18 |
1986-04-18 |
Nordisk Gentofte |
Insulinpraeparat
|
|
CA1291036C
(fr)
*
|
1986-04-23 |
1991-10-22 |
Edwin I. Stoltz |
Administration de medicaments par voie nasale
|
|
US5179079A
(en)
*
|
1986-12-16 |
1993-01-12 |
Novo Nordisk A/S |
Nasal formulation and intranasal administration therewith
|
|
NZ222907A
(en)
*
|
1986-12-16 |
1990-08-28 |
Novo Industri As |
Preparation for intranasal administration containing a phospholipid absorption enhancing system
|
|
CA1335076C
(fr)
*
|
1987-04-01 |
1995-04-04 |
Hanna R. Kowarski |
Composition pharmaceutique et mode d'administration par voie intranasale
|
|
US5112804A
(en)
*
|
1987-04-01 |
1992-05-12 |
Temple University Of The Commonwealth System Of Higher Education |
Pharmaceutical composition and method of intranasal administration
|
|
US6645504B1
(en)
|
1987-06-24 |
2003-11-11 |
Autoimmune Inc. |
Bystander suppression of type I diabetes by oral administration of glucagon
|
|
US4994439A
(en)
*
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
JPH0713372B2
(ja)
*
|
1989-02-14 |
1995-02-15 |
鹿島建設株式会社 |
砂質土層における構造物基礎の構築方法
|
|
IL99699A
(en)
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
|
JPH04126437U
(ja)
*
|
1991-05-10 |
1992-11-18 |
八木アンテナ株式会社 |
光受信機
|
|
US5338837A
(en)
*
|
1991-12-13 |
1994-08-16 |
The Trustees Of Princeton University |
Glycosylated steroid derivatives for transport across biological membranes and process for making same
|
|
US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
|
US5693769A
(en)
*
|
1991-12-13 |
1997-12-02 |
Transcell Technologies, Inc. |
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
|
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
|
US6509006B1
(en)
|
1992-07-08 |
2003-01-21 |
Inhale Therapeutic Systems, Inc. |
Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
|
|
IL108748A0
(en)
*
|
1993-02-23 |
1994-08-26 |
Univ Princeton |
Solution and solid-phase formation of glycosidic linkages
|
|
US5639866A
(en)
*
|
1993-02-23 |
1997-06-17 |
Princeton University |
Single-step formation of multiple glycosidic linkages
|
|
US5747445A
(en)
*
|
1993-06-24 |
1998-05-05 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
|
TW402506B
(en)
|
1993-06-24 |
2000-08-21 |
Astra Ab |
Therapeutic preparation for inhalation
|
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
|
US5506203C1
(en)
*
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
|
IS1796B
(is)
*
|
1993-06-24 |
2001-12-31 |
Ab Astra |
Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
|
|
US5830853A
(en)
*
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
|
ATE416755T1
(de)
|
1994-03-07 |
2008-12-15 |
Nektar Therapeutics |
Verfahren und zusammensetzung für die pulmonale darreichung von insulin
|
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
|
US6165976A
(en)
*
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
|
JP3687993B2
(ja)
*
|
1994-06-24 |
2005-08-24 |
シスメックス株式会社 |
インシュリン標準液
|
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
|
EE9700138A
(et)
|
1994-12-22 |
1997-12-15 |
Astra Aktiebolag |
Aerosoolravimvormid
|
|
US5780014A
(en)
*
|
1995-04-14 |
1998-07-14 |
Inhale Therapeutic Systems |
Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
|
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
US6653492B2
(en)
|
2001-05-02 |
2003-11-25 |
Novo Nordick A/S |
Preparation of bile acids
|
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
CN102596175A
(zh)
|
2009-07-06 |
2012-07-18 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
|
PL2611458T3
(pl)
|
2010-08-30 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
|
|
WO2012096276A1
(fr)
*
|
2011-01-13 |
2012-07-19 |
株式会社カネカ |
Promoteur d'absorption percutanée et préparation cutanée externe
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
EP3229828B1
(fr)
|
2014-12-12 |
2023-04-05 |
Sanofi-Aventis Deutschland GmbH |
Formulation à rapport fixe d'insuline glargine/lixisenatide
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|